FY2024 EPS Estimates for ABVX Decreased by Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX) – Equities researchers at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for shares of ABIVAX Société Anonyme in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.08) per share for the year, down from their previous forecast of ($2.93). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.09) EPS and FY2028 earnings at ($0.84) EPS.

Other equities analysts have also recently issued reports about the stock. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $38.67.

ABIVAX Société Anonyme Stock Up 0.6 %

ABVX stock opened at $6.84 on Thursday. The business has a 50-day simple moving average of $6.70 and a 200 day simple moving average of $8.60. ABIVAX Société Anonyme has a 52 week low of $5.50 and a 52 week high of $17.02.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP purchased a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at approximately $144,000. Stonepine Capital Management LLC purchased a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth approximately $110,000. Shay Capital LLC purchased a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth $366,000. Millennium Management LLC lifted its position in shares of ABIVAX Société Anonyme by 44.2% during the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after buying an additional 285,542 shares in the last quarter. Finally, Citadel Advisors LLC raised its position in shares of ABIVAX Société Anonyme by 83.5% during the 4th quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after purchasing an additional 389,247 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.